Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
Koirala P, Roth ME, Gill J, Piperdi S, Chinai JM, Geller DS, Hoang BH, Park A, Fremed MA, Zang X, Gorlick R
Abstract
Osteosarcoma patient survival has remained stagnant for 30 years. Novel therapeutic approaches are needed to improve outcomes. We examined the expression of Programmed Death Ligand 1 (PD-L1) and defined the tumor immune microenvironment to assess the prognostic utility in osteosarcoma. PD-L1 expression in osteosarcoma was examined in two patient cohorts using immunohistochemistry (IHC) (n = 48, n = 59) and expression was validated using quantitative real time PCR (n = 21) and western blotting (n = 9). IHC was used to determine the presence of tumor infiltrating lymphocytes and antigen-presenting cells (APCs) in the tumor. Expression of PD-L1 was correlated with immune cell infiltration and event-free-survival (EFS). The 25% of primary osteosarcoma tumors that express PD-L1 were more likely to contain cells that express PD-1 than PD-L1 negative tumors (91.7% vs 47.2%, p = 0.002). Expression of PD-L1 was significantly associated with the presence of T cells, dendritic cells, and natural killer cells. Although all immune cell types examined were present in osteosarcoma samples, only infiltration by dendritic cells (28.3% vs. 83.9%, p = 0.001) and macrophages (45.5% vs. 84.4%, p = 0.031) were associated with worse five-year-EFS. PD-L1 expression was significantly associated with poorer five-year-EFS (25.0%. vs. 69.4%, p = 0.014). Further studies in osteosarcoma are needed to determine if targeting the PD-L1:PD-1 axis improves survival.
Abstract of "Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma" by Koirala P, Roth ME, Gill J et al., https://doi.org/10.1038/srep30093, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.
Record
- Archive ID
- doi:10.1038/srep30093
- Published
- Jul 26, 2016
- Venue
- Scientific reports
- DOI
- 10.1038/srep30093
- PubMed
- 27456063
- PMC
- PMC4960483
- License
- CC-BY
- Provenance
- europepmc